G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
The wind is positively howling here as I write this, as it is over several states west and south of me. It’s currently in the 40s so not terribly cold, but I’d have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results